|Dosage Form||Tablet (oral; 250 mg)|
|Company||Agios Pharmaceuticals Inc.|
- To treat acute myeloid leukemia with a susceptible IDH1 mutation.
- To treat relapsed or refractory acute myeloid leukemia in adults.
- To treat novel acute myeloid leukemia in adults who are ≥ 75 years of age or who are not eligible for the use of intensive induction chemotherapy.